Back
 

View:
Mini 
BasicThis view is available after user registration.
 
ShortThis view is available when you buy a license.
 
StandardThis view is available when you buy a license.
 
CompleteThis view is available when you buy a license.
 

PAED B-NHL 2013, Rituximab 375, B-non-Hodgkin Lymphoma

Protocol-ID: 1884 V1.0 (Mini), PAED B-NHL 2013, RR, B-NHL
Study protocol, available to authorized participants only.

Indication(s)

  • NHL, B-Cell Type, Burkitt's Lymphoma; ICD-10 C83.7
  • NHL, B-Cell Type, Diffuse Large Cell (CD20+); ICD-10 C83.3

Links

  • The trial B-NHL 2013 is a collaborative prospective, multi-national, multi-center, randomized trial with participating centers of the NHL-BFM group (Austria, Switzerland, Czech Republic, Germany) and the Scandinavian NOPHO group (Denmark, Finland, Norway, Sweden). The aim of the trial is to evaluate the role of rituximab in the treatment of mature aggressive B-cell Non-Hodgkin lymphoma and leukemia (B-NHL and B-AL) in children and adolescents. [clinicaltrials.gov]
The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti.

Valid since: 13.12.2021